

## Press Release

09 –VIV – 07

17 June 2009

### **Vivacta raises \$4.5 million to commercialise piezofilm technology**

**Sittingbourne, Kent UK, 16 June 2009** – Vivacta announced today that following successful development of its TSH (Thyroid Function) test, together with prototype commercial readers it has closed a \$4.5 million financing round that was fully subscribed by existing investors. Neil Butler Vivacta's CEO commented "the success of this financing round underpins the support we have from our shareholders and signals their confidence that our ultrasensitive immunochemistry platform will reset the benchmark for diagnosis at the point-of-care. The clinical evaluation of the system has now commenced and we anticipate achieving regulatory clearance within 12 months. The cartridge pilot manufacturing facility has commenced weekly manufacturing campaigns for internal evaluation. Validation of the facility and product is planned for later this year".

Vivacta's technology was recently presented at the influential Oak Ridge Conference. Further announcements regarding commercialisation of the system are anticipated in the coming months.

Vivacta's current investors include AGF Private Equity, HBM Bioventures, Spark Ventures and the original sponsor Viking Technologies.

- ends -

Issued on behalf of Vivacta by De Facto Communications

For further information, contact:

Kevin Payne	De Facto	44 207 861 3023	<a href="mailto:k.payne@defacto.com">k.payne@defacto.com</a>
Neil Butler	Vivacta	44 1795 419400	<a href="mailto:nb@vivacta.com">nb@vivacta.com</a>

#### **About Vivacta:**

Vivacta Limited is a medical diagnostic company developing a patented ultra-sensitive Piezofilm-based technique for rapid point-of-care (PoC) testing. This novel technology can quickly deliver a laboratory quality analysis from a 30µL drop of blood. Based in the Kent Science Park Vivacta has strong venture capital funding and an ambitious growth strategy designed to rapidly commercialise its innovative product. Vivacta's lead product is a diagnostic for thyroid function offering a quantitative test for TSH. Work has already commenced on additional pipeline tests. Information on Vivacta and its technology can be found at <http://www.vivacta.com/>.

#### **About HBM BioVentures**

HBM BioVentures invests worldwide in private and small-cap public companies in the human medicine / biotechnology, diagnostics and medical technology sectors. With assets of Eur 500 million, HBM BioVentures has holdings in over 40 life science companies in Europe, North America and China. Out of

HBM BioVentures' private portfolio, more than 25 companies went public or were sold to a strategic partner. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN) For more details, visit: <http://www.hmbioventures.com>

### **About AGF Private Equity**

With close to €2Bn under management, AGF Private Equity, a member of the Allianz Group, is specialized in non-listed investments. Among the leading French funds, AGF Private Equity's venture branch manages €300M, and has invested in more than 60 high tech companies. As one of the most active venture firms in Europe, AGF Private Equity is a strong partner of growth companies. For more details, visit <http://www.agfpe.com/>.

### **SPARK Ventures**

SPARK Ventures is the leading quoted early-stage venture capital company in Europe. It manages £240 million on behalf of major institutional investors, leading UK universities, and three quoted venture capital trusts. SPARK invests in entrepreneurs to create dynamic businesses in the technology, media, telecoms and healthcare & life sciences sectors. As well as capital, it brings a wealth of experience of developing high growth companies from early stage through to IPO or trade sale, adding value to its investments through active support and strategic direction. The company, which was formerly known as NewMedia SPARK, announced its re-launch as SPARK Ventures in October. For more details, visit: [www.sparkventures.com](http://www.sparkventures.com)